These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1680990)

  • 21. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
    Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum immunosuppressive acidic protein in renal cell carcinoma.
    Ueda T
    Urol Res; 1986; 14(2):101-3. PubMed ID: 3727211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma.
    Igarashi T; Tobe T; Kuramochi H; Akakura K; Ichikawa T; Hamano S; Suzuki N; Furuya Y; Ito H
    Jpn J Clin Oncol; 2001 Jan; 31(1):13-7. PubMed ID: 11256835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma.
    Igarashi T; Murakami S; Isaka S; Okano T; Shimazaki J; Matsuzaki O
    Eur Urol; 1991; 19(4):332-5. PubMed ID: 1915542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors.
    Watanabe J; Nishiyama H; Kawanishi H; Ito M; Kamoto T; Ogawa O
    J Urol; 2005 Jul; 174(1):73-5. PubMed ID: 15947581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunosuppressive acidic protein in human ovarian cancer.
    Lin YH; Chow SN; Chen CK; Chen RJ; Huang SC; Huang GT
    J Formos Med Assoc; 1994 Sep; 93(9):776-80. PubMed ID: 7735007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
    Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
    Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum basic fetoprotein in patients with renal cell carcinoma.
    Gohji K; Ishii M; Nagata H; Matsumoto O; Kamidono S
    Cancer; 1990 Mar; 65(6):1405-11. PubMed ID: 1689608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive substance in the sera of head and neck cancer patients.
    Yamanaka N; Harabuchi Y; Himi T; Kataura A
    Cancer; 1988 Oct; 62(7):1293-8. PubMed ID: 3416271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum copper and zinc levels in patients with malignant neoplasm of the urogenital tract].
    Sanada S; Ogura K; Kiriyama T; Yoshida O
    Hinyokika Kiyo; 1985 Aug; 31(8):1299-316. PubMed ID: 4083194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two cases of urothelial tumor with high serum level of carcinoembryonic antigen and TA-4.
    Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Okamoto S
    Urol Int; 1993; 51(2):105-7. PubMed ID: 8351752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 13,14-Dihydro-15-keto-prostaglandin F2 alpha in patients with urogenital tumors.
    Dunzendorfer U; Zahradnik HP; Gerster K
    Urol Int; 1980; 35(3):171-5. PubMed ID: 6155727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Synchronous triple urogenital cancer (renal cancer, bladder cancer, prostatic cancer): a case report].
    Takada T; Honda M; Momohara C; Komori K; Fujioka H
    Hinyokika Kiyo; 2002 Apr; 48(4):239-42. PubMed ID: 12048939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum beta-2-microglobulin levels in urological cancer.
    Bunning RA; Haworth SL; Cooper EH
    J Urol; 1979 May; 121(5):624-5. PubMed ID: 86616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract.
    Kondo T; Tanabe K
    Int J Urol; 2012 Aug; 19(8):710-21. PubMed ID: 22515472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma.
    Sanders I; Holdenrieder S; Walgenbach-Brünagel G; von Ruecker A; Kristiansen G; Müller SC; Ellinger J
    Int J Urol; 2012 Nov; 19(11):1017-25. PubMed ID: 22788411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive acidic protein detects high nuclear grade localized renal cell carcinoma.
    Kawata N; Yamaguchi K; Hirakata H; Hachiya T; Yoshida T; Takimoto Y
    Urology; 2005 Oct; 66(4):736-40. PubMed ID: 16230127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of immunosuppressive acidic protein in patients with esophageal cancer.
    Kogure M; Kashimura S; Matsuyama S; Ohtani S; Saze Z; Odashima Y; Saitoh T; Soeta N; Osuka F; Hoshino Y; Saito T; Terashima S; Terashima M; Gotoh M
    Dis Esophagus; 2008; 21(3):214-9. PubMed ID: 18430101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC; Lin AT; Chen KK; Chang LS
    Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.